Is acotinib/acalabrutinib currently covered by medical insurance?

In China, whether innovative drugs can be included in the medical insurance catalog often determines patient accessibility and the popularity of medication. Acalabrutinib (Acalabrutinib) is a new generation of BTK inhibitor. Since its approval in 2023, medical insurance coverage has become the focus of most concern for patients and clinicians. According to the latest information, acotinib has now achieved medical insurance access in China. This move has greatly reduced the financial burden on patients and improved the clinical accessibility of the drug.

Currently, medical insurance coverage is clearly limited to two groups of people: one is adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have received at least one treatment in the past; the other is adult patients with mantle cell lymphoma (MCL) who have received at least one treatment in the past. This restriction is mainly based on evidence-based medical evidence and pharmacoeconomic considerations, that is, giving priority to ensuring that patients who have failed or cannot tolerate traditional treatments have timely access to innovative treatments.

From the perspective of medical insurance policy, the inclusion of acotinib not only reflects the country’s efforts in promoting precision cancer medicine and the popularization of innovative drugs, but also reflects the important role played by the medical insurance negotiation mechanism in balancing drug prices and clinical value. For patients, this means that expensive imported targeted drugs are no longer an "out of reach" luxury, but a treatment option that can be reasonably afforded with the support of medical insurance.

From the perspective of clinical use, the medical insurance coverage of acotinib will further promote its promotion in the treatment of hematological tumors, allowing more patients to benefit from its relatively better tolerability and efficacy. In the long term, this combination of medical insurance and innovative drugs is expected to accelerate the implementation of more targeted drugs and improve the overall treatment level of domestic hematological tumors.

Reference materials:https://www.calquence.com/